Royalty Report: Medical, Device, cardiac – Collection: 3257

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Medical
  • Device
  • cardiac
  • Therapeutic
  • Supply

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3257

License Grant
The Company has entered into an exclusive, worldwide License Agreement.  This Licensee Agreement gives the Company the right to commercialize the core Direct Mechanical Ventricular Actuation or DMVA technology and bring it to market.
Field of Use
The Company commercializes a new cardiac therapy device consisting of a family of medical products based upon Direct Mechanical Ventricular Actuation (DMVA) cardiac assist technologies. These technologies enable production of a new type of heart assist device for more effectively treating patients with many types of heart failure.

IPSCIO Record ID: 3096

License Grant
The Licensee entered into an exclusive royalty-based license agreement with a University which granted the Licensee an exclusive right to certain inventions, patents and patent applications.
Field of Use
The Licensee develops Ventricular Assist Devices.  A ventricular assist device (VAD), is a mechanical circulatory device that is used to partially or completely replace the function of a failing heart. Some VADs are intended for short term use, typically for patients recovering from heart attacks or heart surgery, while others are intended for long term use (months to years and in some cases for life), typically for patients suffering from congestive heart failure.

IPSCIO Record ID: 257804

License Grant
The parties are adverse parties following currently pending litigation matters, which are being terminated pursuant to a Settlement Agreement.

The parties are engaged in, inter alia, the design, development, manufacture, and sale of CRM Products.

Pursuant to the Settlement Agreement, the parties have agreed to terminate certain cases and have agreed to enter into a cross licensing of certain rights under the Licensed Patents and Sublicensable Patents.

Licensor grants a non-exclusive, irrevocable, perpetual, worldwide license or sublicense, as the case may be, without the right to sublicense, under all Licensed Patents of Licensor to make, have made, use, sell, have sold, offer to sell, distribute, have distributed, and otherwise dispose of CRM Products, including supplying or causing to be supplied components thereof for use therein, and further including importing CRM Products, including components thereof for use therein, into any jurisdiction where Licensed Patents of Licensor are effective.

Licensor shall grant the right and option until the expiration of thirty (30) months from the Effective Date or ninety (90) days from the date Licensor exercises its option, whichever is later in time, to obtain a non-exclusive, worldwide, non-transferable, license under the specific Patents.

License Property
CRM Products means devices for monitoring or electrically stimulating or shocking the heart which are suitable for chronic implantation, in whole or in part, by or with human patients. The term CRM Products includes, without limitation cardiac pacemakers, antitachycardia pacemakers, cardiac resynchronization therapy systems, cardioverters, and defibrillators, including combinations thereof; loop recording systems, implantable cardiac monitoring systems, implantable hemodynamic monitoring systems, pulse generators and other waveform generators for such devices; cardiac lead implant catheters and associated tools; leads, electrodes, sensors, capacitors, batteries, power sources, and all other components for such devices; mechanisms for coupling such generators in a stimulating, shocking, sensing, or monitoring relationship to the heart; and data dispensing, processing, and gathering systems for such devices, including programmers, pacing system analyzers, defibrillation system analyzers, testers, encoders, decoders, transtelephonic and other remote monitoring systems and services for use with implantable devices, transmitters, receivers, and computer software-controlled systems, and including the software.
Field of Use
The field of use is the medical (pacemaker) industry.

IPSCIO Record ID: 257717

License Grant
The parties are adverse parties following currently pending litigation matters, which are being terminated pursuant to a Settlement Agreement.

The parties are engaged in, inter alia, the design, development, manufacture, and sale of CRM Products.

Pursuant to the Settlement Agreement, the parties have agreed to terminate certain cases and have agreed to enter into a cross licensing of certain rights under the Licensed Patents and Sublicensable Patents.

Licensor grants a non-exclusive, irrevocable, perpetual, worldwide license or sublicense, as the case may be, without the right to sublicense, under all Licensed Patents of Licensor to make, have made, use, sell, have sold, offer to sell, distribute, have distributed, and otherwise dispose of CRM Products, including supplying or causing to be supplied components thereof for use therein, and further including importing CRM Products, including components thereof for use therein, into any jurisdiction where Licensed Patents of Licensor are effective.

Licensor grants the right and option for a period of thirty (30) months from the Effective Date to obtain a non-exclusive, worldwide, non-transferable, royalty-bearing license under the CIC Patents.

License Property
CRM Products means devices for monitoring or electrically stimulating or shocking the heart which are suitable for chronic implantation, in whole or in part, by or with human patients. The term CRM Products includes, without limitation cardiac pacemakers, antitachycardia pacemakers, cardiac resynchronization therapy systems, cardioverters, and defibrillators, including combinations thereof; loop recording systems, implantable cardiac monitoring systems, implantable hemodynamic monitoring systems, pulse generators and other waveform generators for such devices; cardiac lead implant catheters and associated tools; leads, electrodes, sensors, capacitors, batteries, power sources, and all other components for such devices; mechanisms for coupling such generators in a stimulating, shocking, sensing, or monitoring relationship to the heart; and data dispensing, processing, and gathering systems for such devices, including programmers, pacing system analyzers, defibrillation system analyzers, testers, encoders, decoders, transtelephonic and other remote monitoring systems and services for use with implantable devices, transmitters, receivers, and computer software-controlled systems, and including the software.
Field of Use
The field of use is the pacemaker monitoring industry.

IPSCIO Record ID: 29383

License Grant
This agreement between a Canadian Corporation and a Canadian Licensor, under which the Corporation agreed to fund a substantial portion of the Licensor's remaining research efforts relating to artificial heart technology. The Corporation acquired joint ownership with of the technology arising from the Licensor's research under the Research Agreement to market the product and certain other related technologies.
License Property
The License refers to the development and sale of ventricular assist devices, particularly our Levacor Rotary VAD (Levacor VAD or Levacor). VADs are mechanical assist devices that supplement the circulatory function of the heart by re-routing blood flow through a mechanical pump allowing for the restoration of normal blood circulation.
Field of Use
The rights granted apply to medical devices relating to the healthcare and pharmaceutical industry.

IPSCIO Record ID: 1290

License Grant
The University granted the exclusive, world-wide right and license to use and sublicense certain licensed technology in exchange for annual royalties beginning in February 2010.
License Property
The PediaFlow VAD is intended for use in newborns and infants and has been primarily funded by the National Institutes of Health (NIH).  The implantable pediatric PediaFlow VAD is intended for use for bridge to transplant or as a bridge to recovery in the neonate (newborn) to infant population. This fully magnetically levitated miniature rotary blood pump is being designed.  VADs are mechanical assist devices that supplement the circulatory function of the heart by re-routing blood flow through a mechanical pump allowing for the restoration of normal blood circulation. VADs are used for treatment of patients with severe heart failure, including patients whose hearts are irreversibly damaged and cannot be treated effectively by medical or surgical means other than transplant. Bridge-to-Transplant therapy (BTT) therapy involves implanting a VAD in a transplant-eligible patient to maintain or improve the patient’s health until a donor heart becomes available.  In February 2011, the FDA granted Humanitarian Use Device (HUD) designation for the PediaFlow VAD.
Field of Use
The Licensee, in conjunction with a consortium have been developing a small, magnetically levitated, rotary pediatric Ventricular Assist Device or PediaFlow VAD.

IPSCIO Record ID: 7203

License Grant
The Licensor entered into an exclusive, worldwide out-licensing arrangement with the Licensee, in regards to BL-1040.

The Licensee is obligated to use commercially reasonable efforts to complete clinical development of, and to commercialize, BL-1040 or a product related thereto for use in the prevention, mitigation and treatment of injury to the myocardial tissue of the heart.

License Property
BL-1040, is a novel resorbable polymer solution for use in the prevention of cardiac remodeling in patients who suffered an AMI. Preventing cardiac remodeling following an AMI may prevent transition to congestive heart failure and/or improve patient survival over the long term. Following an AMI, BL-1040 is administered via intracoronary injection. Upon contact with damaged cardiac tissue, the liquid BL-1040 transitions into a gel within the infarcted cardiac tissue and forms a “scaffold” that supports, retains the shape of, and enhances the mechanical strength of the heart muscle during the recovery and repair phases following an AMI.
Field of Use
BL-1040 is being developed as a class III medical device under the FDA’s pre-marketing approval, regulatory pathway.

The Licensee commenced Preservation1, a CE Mark registration clinical trial of BL-1040, now called “Bioabsorbable Cardiac Matrix,” or BCM by the Licensee. Preservation 1 aims to evaluate the safety and effectiveness of BL-1040 (BCM) for prevention of ventricular remodeling and congestive heart failure when administered following AMI.

IPSCIO Record ID: 120693

License Grant
A semi-exclusive license under an issued U.S. patent for technology to conduct temporary ventricular defibrillation.
License Property
Defibrillation is a type of abnormal heart rhythm.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 1291

License Grant
The Licensee entered into a License Agreement with a University which granted the Licensee an exclusive right to certain technology and patents in exchange for annual royalties.
License Property
VADs are mechanical assist devices that supplement the circulatory function of the heart by re-routing blood flow through a mechanical pump allowing for the restoration of normal blood circulation.
Field of Use
The Licensee is focused on the development and sale of Ventricular Assist Device (VAD), particularly the Levacor VAD.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.